nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclobenzaprine—migraine—Prednisone—systemic scleroderma	0.348	0.508	CpDpCtD
Cyclobenzaprine—osteoarthritis—Prednisone—systemic scleroderma	0.337	0.492	CpDpCtD
Cyclobenzaprine—CYP1A2—Pentoxifylline—systemic scleroderma	0.0531	0.32	CbGbCtD
Cyclobenzaprine—CYP1A2—Leflunomide—systemic scleroderma	0.0507	0.305	CbGbCtD
Cyclobenzaprine—CYP2D6—Captopril—systemic scleroderma	0.0328	0.197	CbGbCtD
Cyclobenzaprine—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0164	0.0988	CbGbCtD
Cyclobenzaprine—CYP3A4—Prednisone—systemic scleroderma	0.0131	0.079	CbGbCtD
Cyclobenzaprine—HTR2A—myenteric nerve plexus—systemic scleroderma	0.00314	0.32	CbGeAlD
Cyclobenzaprine—HTR2A—pulmonary artery—systemic scleroderma	0.00222	0.226	CbGeAlD
Cyclobenzaprine—HTR2A—artery—systemic scleroderma	0.000825	0.084	CbGeAlD
Cyclobenzaprine—HTR2A—endothelium—systemic scleroderma	0.000697	0.0709	CbGeAlD
Cyclobenzaprine—HTR2A—blood vessel—systemic scleroderma	0.000643	0.0654	CbGeAlD
Cyclobenzaprine—HTR2A—connective tissue—systemic scleroderma	0.000329	0.0335	CbGeAlD
Cyclobenzaprine—CYP1A2—digestive system—systemic scleroderma	0.000304	0.031	CbGeAlD
Cyclobenzaprine—HTR2A—smooth muscle tissue—systemic scleroderma	0.000301	0.0307	CbGeAlD
Cyclobenzaprine—CYP1A2—lung—systemic scleroderma	0.000254	0.0259	CbGeAlD
Cyclobenzaprine—HTR2A—digestive system—systemic scleroderma	0.000238	0.0242	CbGeAlD
Cyclobenzaprine—HTR2A—tendon—systemic scleroderma	0.000226	0.0231	CbGeAlD
Cyclobenzaprine—CYP3A4—digestive system—systemic scleroderma	0.00022	0.0224	CbGeAlD
Cyclobenzaprine—CYP2D6—digestive system—systemic scleroderma	0.000217	0.0221	CbGeAlD
Cyclobenzaprine—HTR2A—lung—systemic scleroderma	0.000199	0.0202	CbGeAlD
Cyclobenzaprine—Dyspnoea—Leflunomide—systemic scleroderma	0.000183	0.00131	CcSEcCtD
Cyclobenzaprine—Hypotension—Mycophenolic acid—systemic scleroderma	0.000183	0.00131	CcSEcCtD
Cyclobenzaprine—Discomfort—Lisinopril—systemic scleroderma	0.000182	0.00131	CcSEcCtD
Cyclobenzaprine—Cerebrovascular accident—Methotrexate—systemic scleroderma	0.000182	0.0013	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Leflunomide—systemic scleroderma	0.000181	0.0013	CcSEcCtD
Cyclobenzaprine—Vomiting—Mometasone—systemic scleroderma	0.00018	0.00129	CcSEcCtD
Cyclobenzaprine—Dry mouth—Lisinopril—systemic scleroderma	0.00018	0.00129	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Azathioprine—systemic scleroderma	0.000179	0.00129	CcSEcCtD
Cyclobenzaprine—Rash—Mometasone—systemic scleroderma	0.000179	0.00128	CcSEcCtD
Cyclobenzaprine—Asthenia—Captopril—systemic scleroderma	0.000179	0.00128	CcSEcCtD
Cyclobenzaprine—Dermatitis—Mometasone—systemic scleroderma	0.000179	0.00128	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Leflunomide—systemic scleroderma	0.000178	0.00128	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000178	0.00128	CcSEcCtD
Cyclobenzaprine—Osteoarthritis—Methotrexate—systemic scleroderma	0.000178	0.00128	CcSEcCtD
Cyclobenzaprine—Confusional state—Lisinopril—systemic scleroderma	0.000178	0.00128	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000178	0.00128	CcSEcCtD
Cyclobenzaprine—Headache—Mometasone—systemic scleroderma	0.000178	0.00128	CcSEcCtD
Cyclobenzaprine—Tremor—Mycophenolate mofetil—systemic scleroderma	0.000177	0.00127	CcSEcCtD
Cyclobenzaprine—Insomnia—Mycophenolic acid—systemic scleroderma	0.000177	0.00127	CcSEcCtD
Cyclobenzaprine—Fatigue—Leflunomide—systemic scleroderma	0.000177	0.00127	CcSEcCtD
Cyclobenzaprine—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000176	0.00127	CcSEcCtD
Cyclobenzaprine—Oedema—Lisinopril—systemic scleroderma	0.000176	0.00127	CcSEcCtD
Cyclobenzaprine—Pruritus—Captopril—systemic scleroderma	0.000176	0.00127	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000176	0.00126	CcSEcCtD
Cyclobenzaprine—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.000176	0.00126	CcSEcCtD
Cyclobenzaprine—Constipation—Leflunomide—systemic scleroderma	0.000176	0.00126	CcSEcCtD
Cyclobenzaprine—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000175	0.00125	CcSEcCtD
Cyclobenzaprine—Somnolence—Mycophenolic acid—systemic scleroderma	0.000174	0.00125	CcSEcCtD
Cyclobenzaprine—Agitation—Mycophenolate mofetil—systemic scleroderma	0.000174	0.00125	CcSEcCtD
Cyclobenzaprine—Shock—Lisinopril—systemic scleroderma	0.000174	0.00125	CcSEcCtD
Cyclobenzaprine—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000173	0.00124	CcSEcCtD
Cyclobenzaprine—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000173	0.00124	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000172	0.00124	CcSEcCtD
Cyclobenzaprine—Tachycardia—Lisinopril—systemic scleroderma	0.000172	0.00124	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Azathioprine—systemic scleroderma	0.000172	0.00123	CcSEcCtD
Cyclobenzaprine—Malaise—Mycophenolate mofetil—systemic scleroderma	0.000171	0.00123	CcSEcCtD
Cyclobenzaprine—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000171	0.00122	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Captopril—systemic scleroderma	0.00017	0.00122	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.00017	0.00122	CcSEcCtD
Cyclobenzaprine—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.00017	0.00122	CcSEcCtD
Cyclobenzaprine—Irritability—Methotrexate—systemic scleroderma	0.00017	0.00122	CcSEcCtD
Cyclobenzaprine—Syncope—Mycophenolate mofetil—systemic scleroderma	0.00017	0.00122	CcSEcCtD
Cyclobenzaprine—Erectile dysfunction—Prednisone—systemic scleroderma	0.00017	0.00122	CcSEcCtD
Cyclobenzaprine—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.00017	0.00122	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Leflunomide—systemic scleroderma	0.000169	0.00121	CcSEcCtD
Cyclobenzaprine—Fatigue—Mycophenolic acid—systemic scleroderma	0.000169	0.00121	CcSEcCtD
Cyclobenzaprine—Nausea—Mometasone—systemic scleroderma	0.000168	0.00121	CcSEcCtD
Cyclobenzaprine—Anorexia—Lisinopril—systemic scleroderma	0.000168	0.00121	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000168	0.00121	CcSEcCtD
Cyclobenzaprine—Weight increased—Prednisone—systemic scleroderma	0.000168	0.0012	CcSEcCtD
Cyclobenzaprine—Ataxia—Methotrexate—systemic scleroderma	0.000168	0.0012	CcSEcCtD
Cyclobenzaprine—Constipation—Mycophenolic acid—systemic scleroderma	0.000167	0.0012	CcSEcCtD
Cyclobenzaprine—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000167	0.0012	CcSEcCtD
Cyclobenzaprine—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000166	0.00119	CcSEcCtD
Cyclobenzaprine—Hypotension—Lisinopril—systemic scleroderma	0.000165	0.00118	CcSEcCtD
Cyclobenzaprine—Dizziness—Captopril—systemic scleroderma	0.000165	0.00118	CcSEcCtD
Cyclobenzaprine—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000164	0.00118	CcSEcCtD
Cyclobenzaprine—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000164	0.00117	CcSEcCtD
Cyclobenzaprine—Urticaria—Leflunomide—systemic scleroderma	0.000163	0.00117	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Leflunomide—systemic scleroderma	0.000162	0.00116	CcSEcCtD
Cyclobenzaprine—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000162	0.00116	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000161	0.00116	CcSEcCtD
Cyclobenzaprine—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000161	0.00116	CcSEcCtD
Cyclobenzaprine—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000161	0.00116	CcSEcCtD
Cyclobenzaprine—Myocardial infarction—Prednisone—systemic scleroderma	0.000161	0.00116	CcSEcCtD
Cyclobenzaprine—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000161	0.00116	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000161	0.00115	CcSEcCtD
Cyclobenzaprine—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000161	0.00115	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Azathioprine—systemic scleroderma	0.00016	0.00115	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.00016	0.00115	CcSEcCtD
Cyclobenzaprine—Insomnia—Lisinopril—systemic scleroderma	0.00016	0.00115	CcSEcCtD
Cyclobenzaprine—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000159	0.00114	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Lisinopril—systemic scleroderma	0.000158	0.00114	CcSEcCtD
Cyclobenzaprine—Vomiting—Captopril—systemic scleroderma	0.000158	0.00114	CcSEcCtD
Cyclobenzaprine—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000158	0.00113	CcSEcCtD
Cyclobenzaprine—Dyspnoea—Lisinopril—systemic scleroderma	0.000157	0.00113	CcSEcCtD
Cyclobenzaprine—Rash—Captopril—systemic scleroderma	0.000157	0.00113	CcSEcCtD
Cyclobenzaprine—Dermatitis—Captopril—systemic scleroderma	0.000157	0.00113	CcSEcCtD
Cyclobenzaprine—Somnolence—Lisinopril—systemic scleroderma	0.000157	0.00113	CcSEcCtD
Cyclobenzaprine—Headache—Captopril—systemic scleroderma	0.000156	0.00112	CcSEcCtD
Cyclobenzaprine—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000156	0.00112	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Lisinopril—systemic scleroderma	0.000155	0.00111	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000155	0.00111	CcSEcCtD
Cyclobenzaprine—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000155	0.00111	CcSEcCtD
Cyclobenzaprine—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000155	0.00111	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Lisinopril—systemic scleroderma	0.000153	0.0011	CcSEcCtD
Cyclobenzaprine—Eosinophilia—Methotrexate—systemic scleroderma	0.000152	0.00109	CcSEcCtD
Cyclobenzaprine—Fatigue—Lisinopril—systemic scleroderma	0.000152	0.00109	CcSEcCtD
Cyclobenzaprine—Shock—Mycophenolate mofetil—systemic scleroderma	0.000152	0.00109	CcSEcCtD
Cyclobenzaprine—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000151	0.00109	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Leflunomide—systemic scleroderma	0.000151	0.00109	CcSEcCtD
Cyclobenzaprine—Constipation—Lisinopril—systemic scleroderma	0.000151	0.00108	CcSEcCtD
Cyclobenzaprine—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000151	0.00108	CcSEcCtD
Cyclobenzaprine—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000149	0.00107	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Azathioprine—systemic scleroderma	0.000149	0.00107	CcSEcCtD
Cyclobenzaprine—Nausea—Captopril—systemic scleroderma	0.000148	0.00106	CcSEcCtD
Cyclobenzaprine—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000147	0.00106	CcSEcCtD
Cyclobenzaprine—Asthenia—Leflunomide—systemic scleroderma	0.000147	0.00106	CcSEcCtD
Cyclobenzaprine—Hallucination—Prednisone—systemic scleroderma	0.000147	0.00105	CcSEcCtD
Cyclobenzaprine—Pancytopenia—Methotrexate—systemic scleroderma	0.000146	0.00105	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Lisinopril—systemic scleroderma	0.000145	0.00104	CcSEcCtD
Cyclobenzaprine—Pruritus—Leflunomide—systemic scleroderma	0.000145	0.00104	CcSEcCtD
Cyclobenzaprine—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000144	0.00104	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000144	0.00104	CcSEcCtD
Cyclobenzaprine—Dizziness—Azathioprine—systemic scleroderma	0.000144	0.00103	CcSEcCtD
Cyclobenzaprine—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000143	0.00103	CcSEcCtD
Cyclobenzaprine—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000142	0.00102	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000141	0.00101	CcSEcCtD
Cyclobenzaprine—Asthenia—Mycophenolic acid—systemic scleroderma	0.000141	0.00101	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Leflunomide—systemic scleroderma	0.00014	0.00101	CcSEcCtD
Cyclobenzaprine—Urticaria—Lisinopril—systemic scleroderma	0.00014	0.00101	CcSEcCtD
Cyclobenzaprine—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.00014	0.001	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Lisinopril—systemic scleroderma	0.000139	0.001	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000139	0.000996	CcSEcCtD
Cyclobenzaprine—Pruritus—Mycophenolic acid—systemic scleroderma	0.000139	0.000995	CcSEcCtD
Cyclobenzaprine—Vomiting—Azathioprine—systemic scleroderma	0.000138	0.000992	CcSEcCtD
Cyclobenzaprine—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000138	0.000989	CcSEcCtD
Cyclobenzaprine—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000137	0.000986	CcSEcCtD
Cyclobenzaprine—Drowsiness—Methotrexate—systemic scleroderma	0.000137	0.000985	CcSEcCtD
Cyclobenzaprine—Rash—Azathioprine—systemic scleroderma	0.000137	0.000984	CcSEcCtD
Cyclobenzaprine—Dermatitis—Azathioprine—systemic scleroderma	0.000137	0.000983	CcSEcCtD
Cyclobenzaprine—Headache—Azathioprine—systemic scleroderma	0.000136	0.000978	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000136	0.000977	CcSEcCtD
Cyclobenzaprine—Dizziness—Leflunomide—systemic scleroderma	0.000136	0.000975	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000134	0.000964	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000134	0.000962	CcSEcCtD
Cyclobenzaprine—Stomatitis—Methotrexate—systemic scleroderma	0.000134	0.000961	CcSEcCtD
Cyclobenzaprine—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000132	0.000949	CcSEcCtD
Cyclobenzaprine—Arrhythmia—Prednisone—systemic scleroderma	0.000132	0.000946	CcSEcCtD
Cyclobenzaprine—Sweating—Methotrexate—systemic scleroderma	0.000132	0.000945	CcSEcCtD
Cyclobenzaprine—Vomiting—Leflunomide—systemic scleroderma	0.000131	0.000937	CcSEcCtD
Cyclobenzaprine—Alopecia—Prednisone—systemic scleroderma	0.00013	0.000935	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Lisinopril—systemic scleroderma	0.00013	0.000933	CcSEcCtD
Cyclobenzaprine—Dizziness—Mycophenolic acid—systemic scleroderma	0.00013	0.00093	CcSEcCtD
Cyclobenzaprine—Rash—Leflunomide—systemic scleroderma	0.000129	0.000929	CcSEcCtD
Cyclobenzaprine—Dermatitis—Leflunomide—systemic scleroderma	0.000129	0.000928	CcSEcCtD
Cyclobenzaprine—Nausea—Azathioprine—systemic scleroderma	0.000129	0.000927	CcSEcCtD
Cyclobenzaprine—Headache—Leflunomide—systemic scleroderma	0.000129	0.000923	CcSEcCtD
Cyclobenzaprine—Agranulocytosis—Methotrexate—systemic scleroderma	0.000128	0.00092	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000127	0.000914	CcSEcCtD
Cyclobenzaprine—Asthenia—Lisinopril—systemic scleroderma	0.000127	0.000909	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000126	0.000907	CcSEcCtD
Cyclobenzaprine—Pruritus—Lisinopril—systemic scleroderma	0.000125	0.000896	CcSEcCtD
Cyclobenzaprine—Vomiting—Mycophenolic acid—systemic scleroderma	0.000125	0.000894	CcSEcCtD
Cyclobenzaprine—Rash—Mycophenolic acid—systemic scleroderma	0.000123	0.000886	CcSEcCtD
Cyclobenzaprine—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000123	0.000886	CcSEcCtD
Cyclobenzaprine—Hepatitis—Methotrexate—systemic scleroderma	0.000123	0.000885	CcSEcCtD
Cyclobenzaprine—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000123	0.000881	CcSEcCtD
Cyclobenzaprine—Headache—Mycophenolic acid—systemic scleroderma	0.000123	0.000881	CcSEcCtD
Cyclobenzaprine—Pharyngitis—Methotrexate—systemic scleroderma	0.000122	0.000878	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000122	0.000877	CcSEcCtD
Cyclobenzaprine—Nausea—Leflunomide—systemic scleroderma	0.000122	0.000875	CcSEcCtD
Cyclobenzaprine—Vision blurred—Prednisone—systemic scleroderma	0.000121	0.000868	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Lisinopril—systemic scleroderma	0.000121	0.000866	CcSEcCtD
Cyclobenzaprine—Ill-defined disorder—Prednisone—systemic scleroderma	0.000119	0.000855	CcSEcCtD
Cyclobenzaprine—Agitation—Prednisone—systemic scleroderma	0.000118	0.000847	CcSEcCtD
Cyclobenzaprine—Angioedema—Prednisone—systemic scleroderma	0.000117	0.000842	CcSEcCtD
Cyclobenzaprine—Dizziness—Lisinopril—systemic scleroderma	0.000117	0.000837	CcSEcCtD
Cyclobenzaprine—Nausea—Mycophenolic acid—systemic scleroderma	0.000116	0.000835	CcSEcCtD
Cyclobenzaprine—Malaise—Prednisone—systemic scleroderma	0.000116	0.000831	CcSEcCtD
Cyclobenzaprine—Vertigo—Prednisone—systemic scleroderma	0.000115	0.000828	CcSEcCtD
Cyclobenzaprine—Syncope—Prednisone—systemic scleroderma	0.000115	0.000826	CcSEcCtD
Cyclobenzaprine—Tinnitus—Methotrexate—systemic scleroderma	0.000115	0.000825	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000114	0.000817	CcSEcCtD
Cyclobenzaprine—Loss of consciousness—Prednisone—systemic scleroderma	0.000113	0.00081	CcSEcCtD
Cyclobenzaprine—Vomiting—Lisinopril—systemic scleroderma	0.000112	0.000805	CcSEcCtD
Cyclobenzaprine—Rash—Lisinopril—systemic scleroderma	0.000111	0.000798	CcSEcCtD
Cyclobenzaprine—Convulsion—Prednisone—systemic scleroderma	0.000111	0.000798	CcSEcCtD
Cyclobenzaprine—Dermatitis—Lisinopril—systemic scleroderma	0.000111	0.000798	CcSEcCtD
Cyclobenzaprine—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000111	0.000796	CcSEcCtD
Cyclobenzaprine—Hypertension—Prednisone—systemic scleroderma	0.000111	0.000796	CcSEcCtD
Cyclobenzaprine—Headache—Lisinopril—systemic scleroderma	0.000111	0.000793	CcSEcCtD
Cyclobenzaprine—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000109	0.000785	CcSEcCtD
Cyclobenzaprine—Myalgia—Prednisone—systemic scleroderma	0.000109	0.000785	CcSEcCtD
Cyclobenzaprine—Anxiety—Prednisone—systemic scleroderma	0.000109	0.000782	CcSEcCtD
Cyclobenzaprine—Alopecia—Methotrexate—systemic scleroderma	0.000109	0.000782	CcSEcCtD
Cyclobenzaprine—Discomfort—Prednisone—systemic scleroderma	0.000108	0.000775	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000106	0.000759	CcSEcCtD
Cyclobenzaprine—Dysgeusia—Methotrexate—systemic scleroderma	0.000105	0.000754	CcSEcCtD
Cyclobenzaprine—Nausea—Lisinopril—systemic scleroderma	0.000105	0.000752	CcSEcCtD
Cyclobenzaprine—Anaphylactic shock—Prednisone—systemic scleroderma	0.000105	0.000752	CcSEcCtD
Cyclobenzaprine—Oedema—Prednisone—systemic scleroderma	0.000105	0.000752	CcSEcCtD
Cyclobenzaprine—Shock—Prednisone—systemic scleroderma	0.000103	0.00074	CcSEcCtD
Cyclobenzaprine—Tachycardia—Prednisone—systemic scleroderma	0.000102	0.000734	CcSEcCtD
Cyclobenzaprine—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000102	0.000734	CcSEcCtD
Cyclobenzaprine—Hyperhidrosis—Prednisone—systemic scleroderma	0.000101	0.000727	CcSEcCtD
Cyclobenzaprine—Vision blurred—Methotrexate—systemic scleroderma	0.000101	0.000726	CcSEcCtD
Cyclobenzaprine—Anorexia—Prednisone—systemic scleroderma	9.99e-05	0.000717	CcSEcCtD
Cyclobenzaprine—Ill-defined disorder—Methotrexate—systemic scleroderma	9.95e-05	0.000715	CcSEcCtD
Cyclobenzaprine—Vomiting—Mycophenolate mofetil—systemic scleroderma	9.83e-05	0.000705	CcSEcCtD
Cyclobenzaprine—Rash—Mycophenolate mofetil—systemic scleroderma	9.75e-05	0.0007	CcSEcCtD
Cyclobenzaprine—Dermatitis—Mycophenolate mofetil—systemic scleroderma	9.74e-05	0.000699	CcSEcCtD
Cyclobenzaprine—Headache—Mycophenolate mofetil—systemic scleroderma	9.68e-05	0.000695	CcSEcCtD
Cyclobenzaprine—Malaise—Methotrexate—systemic scleroderma	9.68e-05	0.000694	CcSEcCtD
Cyclobenzaprine—Vertigo—Methotrexate—systemic scleroderma	9.64e-05	0.000692	CcSEcCtD
Cyclobenzaprine—Leukopenia—Methotrexate—systemic scleroderma	9.6e-05	0.000689	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Prednisone—systemic scleroderma	9.55e-05	0.000685	CcSEcCtD
Cyclobenzaprine—Insomnia—Prednisone—systemic scleroderma	9.48e-05	0.00068	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Prednisone—systemic scleroderma	9.41e-05	0.000675	CcSEcCtD
Cyclobenzaprine—Convulsion—Methotrexate—systemic scleroderma	9.3e-05	0.000667	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Prednisone—systemic scleroderma	9.22e-05	0.000662	CcSEcCtD
Cyclobenzaprine—Nausea—Mycophenolate mofetil—systemic scleroderma	9.18e-05	0.000659	CcSEcCtD
Cyclobenzaprine—Myalgia—Methotrexate—systemic scleroderma	9.13e-05	0.000656	CcSEcCtD
Cyclobenzaprine—Chest pain—Methotrexate—systemic scleroderma	9.13e-05	0.000656	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Prednisone—systemic scleroderma	9.11e-05	0.000654	CcSEcCtD
Cyclobenzaprine—Fatigue—Prednisone—systemic scleroderma	9.03e-05	0.000648	CcSEcCtD
Cyclobenzaprine—Discomfort—Methotrexate—systemic scleroderma	9.02e-05	0.000648	CcSEcCtD
Cyclobenzaprine—Constipation—Prednisone—systemic scleroderma	8.96e-05	0.000643	CcSEcCtD
Cyclobenzaprine—Confusional state—Methotrexate—systemic scleroderma	8.83e-05	0.000634	CcSEcCtD
Cyclobenzaprine—Anaphylactic shock—Methotrexate—systemic scleroderma	8.76e-05	0.000629	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Prednisone—systemic scleroderma	8.63e-05	0.00062	CcSEcCtD
Cyclobenzaprine—Thrombocytopenia—Methotrexate—systemic scleroderma	8.57e-05	0.000615	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Prednisone—systemic scleroderma	8.57e-05	0.000615	CcSEcCtD
Cyclobenzaprine—Hyperhidrosis—Methotrexate—systemic scleroderma	8.46e-05	0.000608	CcSEcCtD
Cyclobenzaprine—Anorexia—Methotrexate—systemic scleroderma	8.35e-05	0.000599	CcSEcCtD
Cyclobenzaprine—Urticaria—Prednisone—systemic scleroderma	8.32e-05	0.000597	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Prednisone—systemic scleroderma	8.28e-05	0.000595	CcSEcCtD
Cyclobenzaprine—Hypotension—Methotrexate—systemic scleroderma	8.18e-05	0.000587	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	7.98e-05	0.000573	CcSEcCtD
Cyclobenzaprine—Insomnia—Methotrexate—systemic scleroderma	7.92e-05	0.000568	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Methotrexate—systemic scleroderma	7.86e-05	0.000564	CcSEcCtD
Cyclobenzaprine—Dyspnoea—Methotrexate—systemic scleroderma	7.81e-05	0.00056	CcSEcCtD
Cyclobenzaprine—Somnolence—Methotrexate—systemic scleroderma	7.78e-05	0.000559	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Prednisone—systemic scleroderma	7.72e-05	0.000554	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Methotrexate—systemic scleroderma	7.71e-05	0.000553	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Methotrexate—systemic scleroderma	7.61e-05	0.000546	CcSEcCtD
Cyclobenzaprine—Fatigue—Methotrexate—systemic scleroderma	7.55e-05	0.000542	CcSEcCtD
Cyclobenzaprine—Asthenia—Prednisone—systemic scleroderma	7.52e-05	0.00054	CcSEcCtD
Cyclobenzaprine—Pruritus—Prednisone—systemic scleroderma	7.41e-05	0.000532	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Methotrexate—systemic scleroderma	7.22e-05	0.000518	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Prednisone—systemic scleroderma	7.17e-05	0.000515	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Methotrexate—systemic scleroderma	7.16e-05	0.000514	CcSEcCtD
Cyclobenzaprine—Urticaria—Methotrexate—systemic scleroderma	6.96e-05	0.000499	CcSEcCtD
Cyclobenzaprine—Dizziness—Prednisone—systemic scleroderma	6.93e-05	0.000497	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Methotrexate—systemic scleroderma	6.92e-05	0.000497	CcSEcCtD
Cyclobenzaprine—Vomiting—Prednisone—systemic scleroderma	6.66e-05	0.000478	CcSEcCtD
Cyclobenzaprine—Rash—Prednisone—systemic scleroderma	6.61e-05	0.000474	CcSEcCtD
Cyclobenzaprine—Dermatitis—Prednisone—systemic scleroderma	6.6e-05	0.000474	CcSEcCtD
Cyclobenzaprine—Headache—Prednisone—systemic scleroderma	6.56e-05	0.000471	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Methotrexate—systemic scleroderma	6.45e-05	0.000463	CcSEcCtD
Cyclobenzaprine—Asthenia—Methotrexate—systemic scleroderma	6.28e-05	0.000451	CcSEcCtD
Cyclobenzaprine—Nausea—Prednisone—systemic scleroderma	6.22e-05	0.000447	CcSEcCtD
Cyclobenzaprine—Pruritus—Methotrexate—systemic scleroderma	6.19e-05	0.000445	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Methotrexate—systemic scleroderma	5.99e-05	0.00043	CcSEcCtD
Cyclobenzaprine—Dizziness—Methotrexate—systemic scleroderma	5.79e-05	0.000416	CcSEcCtD
Cyclobenzaprine—Vomiting—Methotrexate—systemic scleroderma	5.57e-05	0.0004	CcSEcCtD
Cyclobenzaprine—Rash—Methotrexate—systemic scleroderma	5.52e-05	0.000396	CcSEcCtD
Cyclobenzaprine—Dermatitis—Methotrexate—systemic scleroderma	5.52e-05	0.000396	CcSEcCtD
Cyclobenzaprine—Headache—Methotrexate—systemic scleroderma	5.49e-05	0.000394	CcSEcCtD
Cyclobenzaprine—Nausea—Methotrexate—systemic scleroderma	5.2e-05	0.000373	CcSEcCtD
